Published in Cancer Weekly, August 17th, 2004
The manuscript, titled "A methionine aminopeptidase-2 inhibitor, PPI-2458 for the treatment of rheumatoid arthritis," appears in the Proceedings of the National Academy of Sciences.
PPI-2458 is a novel, proprietary molecule that acts by irreversibly inhibiting the enzyme methionine aminopeptidase type 2, or MetAP2. PPI-2458 is based on the fumagillin class of compounds. This class of compounds has been shown to prevent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.